Orbitrap Eclipse Tribrid Mass Spectrometer as a Regional Resource

Orbitrap Eclipse Tribrid 质谱仪作为区域资源

• 批准号: 10629013
• 负责人: Fuming Zhang
• 金额: $ 119.85万
• 依托单位: RENSSELAER POLYTECHNIC INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-05 至 2024-09-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10629013
• 关键词: 15 year old; Alzheimer' s Disease; Applications Grants; Biomanufacturing; Biomedical Engineering; Biophysics; Biotechnology; Capital; Cardiac; Cholesterol; Circadian Rhythms; Communities; Core Facility; Disease; Ensure; Experimental Designs; Funding; Human; Immune; Interdisciplinary Study; Investments; Lung; Maintenance; Malignant Neoplasms; Mass Spectrum Analysis; Minor; Molecular; New York; Parkinson Disease; Peer Review; Phosphorylation; Play; Policies; Polysaccharides; Proteomics; Publications; Radial; Renal glomerular disease; Request for Proposals; Research; Resources; Running; Sampling; Spinal cord injury; Technology; Time; United States National Institutes of Health; base; cost; experience; experimental study; human disease; instrument; instrumentation; mass spectrometer; microbiome; operation; programs; quantum; structural biology; success

7. Project Summary/Abstract This S10 Shared Instrumentation Grant Proposal requests funds to acquire an Orbitrap Eclipse Tribrid mass spectrometer (MS). This new Orbitrap will replace our current LTQ Orbitrap XL MS and the TSQ Quantum Ultra MS, both more than 15 years old. This strategic investment will save significant taxpayers’ moneys by replacing two old instruments with just one to reduce the cost of operation. At the same time, the unique capabilities of the Orbitrap Eclipse would greatly enhance the research topics which can be analyzed to meet the needs of our research community, including identification of PTMs including phosphorylation, analysis of glycans, and top- down proteomics. The new Orbitrap will be housed in the Proteomics core facility, in the Center for Biotechnology and Interdisciplinary Studies (CBIS), at RPI. If our proposal is funded, this advanced technology will be available to 30 research groups in the New York Capital Region. There are 20-NIH funded research groups participating in this proposal, nineteen of these are major users of the proposed instrumentation. Overall, this NIH-funded group is very strong with R01, R44, R37, R21, RF1, R35, R03 and accounts for 85% of the AUT. Currently an Orbitrap Eclipse Tribrid mass spectrometer is not available in a radius of 150 miles from RPI and will become an excellent resource in the NY Capital region and beyond. Many of the research programs in this proposal are related to bioengineering, structural biology, molecular biophysics and biomanufacturing. These programs are related to many human diseases, including Alzheimer’s disease, glomerular disease, spinal cord injury, lung recellularization, Parkinson’s disease, circadian rhythm, microbiome in human gut, and immune mechanisms/diseases, cardiac chirality, cancer, cholesterol levels, all of these projects are NIH funded. The user base spans from users with little experience in mass spectrometry that send samples to the facility and fully rely on the expertise of the Proteomics Core director, to highly experienced mass spectroscopists. Dr. Zagorevski will play a key role in designing experiments, running experiments and analyzing the results, making critical scientific contributions to the mass spectrometry field. Under his oversight, the Proteomics core is one of the most successful cores in CBIS with more than 90 peer-reviewed publications in the last 5 years. His outstanding expertise, well-established administration and maintenance policies, commitment to support both major and minor users, and affordable rates for both internal and external users will ensure success of this instrument as a regional resource.

7。项目摘要/摘要 S10共享的仪器赠款提案要求资金获得轨道蚀的三元质量 光谱仪（MS）。这种新的Orbitrap将取代我们当前的LTQ Orbitrap XL MS和TSQ Quantum Ultra MS，都有15多年的历史。这项战略投资将通过更换来节省大量纳税人的款项 两种旧仪器，只有一种来降低运营成本。同时， Orbitrap Eclipse将大大增强可以分析的研究主题，以满足我们的需求 研究社区，包括鉴定PTM，包括磷酸化，聚糖分析以及顶部 降低蛋白质组学。新的Orbitrap将安置在生物技术中心的蛋白质组学核心设施中 RPI和跨学科研究（CBIS）。如果我们的建议是资助的，则将提供该先进技术 到纽约首都地区的30个研究小组。有20个NIH资助的研究小组参加 在此提案中，其中有十个是拟议仪器的主要用户。总体而言，这是NIH资助的 组非常强大，R01，R44，R37，R21，RF1，R35，R03非常强，占AUT的85％。目前 Orbitrap Eclipse Tribrid质谱仪在距RPI 150英里的半径不足，将成为一个 纽约首都地区及其他地区的优质资源。该提案中的许多研究计划是 与生物工程，结构生物学，分子生物物理学和生物制造有关。这些程序是 与许多人类疾病有关，包括阿尔茨海默氏病，肾小球疾病，脊髓损伤，肺 延迟，帕金森氏病，昼夜节律，人类肠道微生物组和免疫 机制/疾病，心脏手性，癌症，胆固醇水平，所有这些项目都是NIH资助的。用户 基本跨越质谱经验很少的用户的基础，这些质谱将样品发送到设施并完全依赖 在蛋白质组学核心主管的专业知识上，经验丰富的质谱学家。 Zagorevski博士 将在设计实验，运行实验和分析结果中发挥关键作用，使得至关重要 对质谱领域的科学贡献。在他的监督下，蛋白质组学核心是 在过去的5年中，CBI中最成功的核心有90多个经过同行评审的出版物。他的杰出 专业知识，良好的管理和维护政策，致力于支持专业和 次要用户以及内部和外部用户的负担得起的费率将确保本工具成功作为一个 区域资源。